We also summarize recent advances in the preclinical and clinical development of different types of TGF‐β‐targeting agents, and discuss their therapeutic potentials and challenges as well as approaches to improve the safety and efficacy of TGF-β pathway-targeted therapy in cancers. Here, TGFB1 is linked to cancer.